文献速递临床试验与 GCP流行病学与生物统计

急性脑出血强化降压集束化治疗试验(INTERACT3):实用性阶梯楔形整群随机对照试验研究方案

INTEnsive care bundle with blood pressure reduction in acute cerebral hemorrhage trial (INTERACT3): study protocol for a pragmatic stepped-wedge cluster-randomized controlled trial.
PubMed 文献 · Trials · 2021-12-20

INTERACT3是一项在低中收入国家110家医院开展的实用性、国际多中心、阶梯楔形整群随机对照试验,目标纳入8360例发病6小时内的成人急性脑出血患者,评估目标导向集束化方案(强化降压、血糖控制、退热及逆转抗凝)相比常规治疗对6个月改良Rankin量表评分的改善效果。

要点

  • INTERACT3为阶梯楔形整群随机对照试验,目标纳入8360例急性脑出血患者,来自110家医院。
  • 干预集束包括强化降压(收缩压目标<140 mmHg)、血糖控制、退热及逆转抗凝。
  • 主要结局为6个月改良Rankin量表评分,采用序贯logistic回归分析。

核心结论

  • INTERACT3作为急性脑出血领域规模最大的临床试验,将按计划评估一种广泛适用的目标导向集束化方案对一种尚未确立明确有效治疗的严重疾病的疗效。

研究设计与样本

  • 实用性、国际多中心、阶梯楔形(4阶段/3步)整群随机对照试验,在低中收入国家110家医院开展,目标纳入8360例发病6小时内的成人(年龄≥18岁)急性脑出血患者,每阶段平均连续纳入19例。

主要发现

  • 样本量8360例在多种假设下提供90%把握度(α=0.05),以检测干预组相比对照标准治疗组主要结局5.6%的绝对改善(平移)。
  • 将收集人口学和基线临床特征、院内管理及7天结局信息,并由中心培训的盲法评估员通过电话访谈评估6个月时躯体功能和健康相关生活质量。

关键数值与推荐

  • 强化降压目标收缩压<140 mmHg。
  • 血糖控制目标:无糖尿病患者6.1-7.8 mmol/L,糖尿病患者7.8-10.0 mmol/L。
  • 退热治疗目标体温≤37.5 °C。
  • 逆转抗凝目标国际标准化比值<1.5,于1小时内达成。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early intensive blood pressure (BP) lowering remains the most promising treatment for acute intracerebral hemorrhage (ICH), despite discordant results between clinical trials and potential variation in the treatment effects by approach to control BP. As the third in a series of clinical trials on this topic, the INTEnsive care bundle with blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT3) aims to determine the effectiveness of a goal-directed care bundle protocol of early physiological control (intensive BP lowering, glycemic control, and pyrexia treatment) and reversal of anticoagulation, in acute ICH. METHODS: INTERACT3 is a pragmatic, international, multicenter, stepped-wedge (4 phases/3 steps), cluster-randomized controlled trial to determine the effectiveness of a multifaceted care package in adult (age ≥ 18 years) patients (target 8360) with acute ICH (< 6 h of onset) recruited from 110 hospitals (average of 19 consecutive patients per phase) in low- and middle-income countries. After a control phase, each hospital implements the intervention (intensive BP lowering, target systolic < 140 mmHg; glucose control, target 6.1-7.8 mmol/L and 7.8-10.0 mmol/L in those without and with diabetes mellitus, respectively; anti-pyrexia treatment to target body temperature ≤ 37.5 °C; and reversal of anticoagulation, target international normalized ratio < 1.5 within 1 h). Information will be obtained on demographic and baseline clinical characteristics, in-hospital management, and 7-day outcomes. Central trained blinded assessors will conduct telephone interviews to assess physical function and health-related quality of life at 6 months. The primary outcome is the modified Rankin scale (mRS) at 6 months analyzed using ordinal logistic regression. The sample size of 8360 subjects provides 90% power (α = 0.05) to detect a 5.6% absolute improvement (shift) in the primary outcome of the intervention versus control standard care, with various assumptions. DISCUSSION: As the largest clinical trial in acute ICH, INTERACT3 is on schedule to provide an assessment of the effectiveness of a widely applicable goal-directed care bundle for a serious condition in which a clearly proven treatment has yet to be established. TRIAL REGISTRATION: ClinicalTrials.gov NCT03209258. Registered on 1 July 2017. Chinese Trial Registry ChiCTR-IOC-17011787. Registered on 28 June 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Song L, Hu X, Ma L, et al. INTEnsive care bundle with blood pressure reduction in acute cerebral hemorrhage trial (INTERACT3): study protocol for a pragmatic stepped-wedge cluster-randomized controlled trial. Trials. 2021. PMID: 34930428. doi:10.1186/s13063-021-05881-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。